Astrazeneca PLC Fundamentals Datasheet and Stock Analysis
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
- Current Price:7,167.00p
- Industry:Health Care
- Sector:Health Care
- ISIN:GB0009895292
- Market Sector:MAIN
- Main Indices:techMARK, FTSE 100, FTSE Eurotop 300, FTSE-350, FTSE All-Share, FTSE All-Share
- Country of register:Great Britain
- Currency:N/A
- Shares in Issue:1,313m
- Market Cap:£95,659m
- Date Listed:13/01/2006
Loading...
Activity Data Not Available
CEO and Executive director: Pascal Soriot CFO & Executive Director: Marc Dunoyer Non-Executive Chairman: Leif Johansson Senior Independent Non-Executive Director: John Varley Non-Executive Dir: Rudy Markham, Marcus Wallenberg, Graham Chipchase, Bruce Burlington, Ann Cairns, Genevieve Berger, Shriti Vadera, Jean-Philippe Courtois Prof Dame Nancy Rothwell
- Registrars:Equiniti
- Address:2 Kingdom Street, London, W2 6BD
- Phone:+44 (0)20 7604 8000
- Website:http://www.astrazeneca.com
2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | |||
---|---|---|---|---|---|---|---|---|---|---|---|
Day/Month | 31/12 | 31/12 | 31/12 | 31/12 | 31/12 | 31/12 | 31/12 | 31/12 | 31/12 | ||
Revenue | $m | 25,711.00 | 26,095.00 | 24,708.00 | 23,002.00 | 22,465.00 | 22,090.00 | 24,384.00 | 26,617.00 | $m | 22,375.75 |
Operating Profit/(loss) | $m | 3,712.00 | 2,137.00 | 4,114.00 | 4,902.00 | 3,677.00 | 3,387.00 | 2,924.00 | 5,162.00 | $m | 0.00 |
Profit Before Tax | $m | 3,267.00 | 1,246.00 | 3,069.00 | 3,552.00 | 2,227.00 | 1,993.00 | 1,548.00 | 3,916.00 | $m | 6,382.07 |
Profit After Tax | $m | 2,571.00 | 1,235.00 | 2,826.00 | 3,406.00 | 2,868.00 | 2,050.00 | 1,227.00 | 3,144.00 | $m | 0.00 |
Profit After Tax (from discontinued operations) | $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | $m | 0.00 |
Overall Profit for the Period | $m | 2,571.00 | 1,235.00 | 2,826.00 | 3,406.00 | 2,868.00 | 2,050.00 | 1,227.00 | 3,144.00 | $m | 0.00 |
EPS Growth | % | (58.79) | (51.96) | 127.55 | 23.77 | (14.13) | (28.27) | (39.41) | 136.89 | % | 23.00 |
Earnings Per Share | ¢ | 204.00 | 98.00 | 223.00 | 276.00 | 237.00 | 170.00 | 103.00 | 244.00 | p | 384.07 |
Op. Cash Flow P/S | ¢ | 5.90 | 5.58 | 2.63 | 3.27 | 2.82 | 2.07 | 2.28 | 3.66 | $ | 0.00 |
Cash Flow P/S Grth | % | 1,304.76 | (5.42) | (52.87) | 24.33 | (13.76) | (26.60) | 10.14 | 60.53 | % | 0.00 |
Net Cash Flow P/S | ¢ | 736.18 | 503.96 | 493.67 | 396.68 | 0.00 | 381.29 | 412.68 | 0.00 | $ | 0.00 |
Capital Exp P/S | $ | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | $ | 0.00 |
Tax Rate | % | 21.30 | 0.88 | 7.96 | 4.15 | 0.00 | (2.71) | 19.29 | 0.00 | % | 0.00 |
P/E Ratio | x | 22.70 | 26.60 | 28.60 | 22.00 | 29.70 | 47.30 | 102.10 | 41.70 | x | 19.30 |
P/E Growth | $ | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.30 | $ | 0.80 |
Turnover Per Share | $ | 2,053.59 | 2,067.75 | 1,954.75 | 1,818.34 | 0.00 | 1,743.49 | 1,874.25 | 0.00 | $ | 0.00 |
Pre-Tax Profit / Share | $ | 260.94 | 98.73 | 242.80 | 280.79 | 0.00 | 157.30 | 118.99 | 0.00 | $ | 0.00 |
Operating Margin | % | 14.44 | 8.19 | 16.65 | 21.31 | 16.37 | 15.33 | 11.99 | 19.39 | % | 0.00 |
ROCE | % | 9.43 | 4.26 | 9.09 | 10.41 | 7.64 | 7.57 | 6.82 | 11.18 | % | 0.00 |
ROE | % | 10.89 | 5.76 | 14.82 | 20.99 | 20.13 | 15.71 | 10.43 | 22.23 | % | 0.00 |
Mkt Cap | $m | 45,258.12 | 57,378.28 | 58,351.90 | 56,144.55 | 67,225.32 | 74,172.49 | 100,431.04 | 97,155.75 | $m | 0.00 |
Dividend Per Share | ¢ | 280.00 | 280.00 | 280.00 | 280.00 | 280.00 | 280.00 | 280.00 | 280.00 | p | 210.86 |
DPS Growth | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | % | 0.00 |
Dividend Yield | % | 6.00 | 4.70 | 4.40 | 4.60 | 4.00 | 3.50 | 2.70 | 2.80 | % | 2.90 |
Dividend Cover | x | 1.80 | 1.53 | 1.52 | 1.54 | 1.53 | 0.61 | 0.37 | 0.87 | x | 0.00 |
Shareholder Funds | $m | 23,224.00 | 19,627.00 | 18,490.00 | 14,854.00 | 14,960.00 | 12,468.00 | 13,127.00 | 15,622.00 | $m | 0.00 |
Net Borrowings | $m | 11,591.00 | 44,831.00 | 88,131.00 | 117,901.00 | (33,241.00) | 142,821.00 | 128,581.00 | (78,321.00) | $m | 0.00 |
Net Assets | $m | 23,253.00 | 19,646.00 | 18,509.00 | 16,669.00 | 16,642.00 | 14,044.00 | 14,596.00 | 15,638.00 | $m | 0.00 |
Net Assets P/S | $ | (221.65) | (1,021.00) | (1,260.84) | (1,784.58) | 0.00 | (1,548.70) | (1,376.25) | 0.00 | $ | 0.00 |
Latest | Forecast | |
---|---|---|
Div Yield | 2.8% | 2.8% |
Div Cover | 0.9% | 1.8% |
Op Margin | 19.4% | 26.8% |
ROCE | 76.3% |
Traded | Action | Notifier | Price | Amount | Value |
---|---|---|---|---|---|
16-Dec-20 | Buy | Philip A J Broadley | 7,625.00p | 1,310 | ,399,887.50 |
16-Dec-20 | Buy | Michel Demare | 7,680.00p | 1,300 | ,399,840 |
16-Dec-20 | Buy | Nazneen Rahman | 7,677.60p | 259 | ,319,884.98 |
16-Dec-20 | Buy | Nazneen Rahman | 7,679.10p | 258 | ,319,812.08 |
16-Dec-20 | Buy | Euan Ashley | 103.04$ | 350 | $29,738.60 |
18-Mar-20 | Buy | Tony Mok | 76.64$ | 500 | $31,598.91 |
18-Mar-20 | Buy | Tony Mok | 76.64$ | 500 | $29,937.52 |
26-Feb-20 | Buy | Tony Mok | 96.00$ | 500 | $39,581.10 |
26-Feb-20 | Buy | Tony Mok | 96.00$ | 500 | $37,500.03 |
17-Feb-20 | Buy | Michel Demare | 7,313.00p | 700 | ,351,191 |
Notifier | Holding | Value |
---|---|---|
Pascal Soriot | 609,188 | ,,013,833 |
Marc Dunoyer | 439,130 | ,727,142.50 |
Marcus Wallenberg | 63,646 | ,598,423.50 |
Leif Johansson | 39,009 | ,818,400.25 |
Graham Chipchase | 3,000 | Ø,750 |
News Title | Date | Time | Source |
---|---|---|---|
Second Price Monitoring Extn | 29-May-20 | 16:41 | RNS |
Price Monitoring Extension | 29-May-20 | 16:35 | RNS |
Imfinzi sustained overall survival in CASPIAN | 29-May-20 | 13:00 | RNS |
Enhertu DESTINY-Gastric01 results from ASCO 2020 | 29-May-20 | 13:00 | RNS |
Tagrisso unprecedented adjuvant lung cancer data | 29-May-20 | 07:00 | RNS |
Director/PDMR Shareholding | 26-May-20 | 10:30 | RNS |
Enhertu US orphan designation in gastric cancer | 22-May-20 | 07:00 | RNS |
AstraZeneca advances response to COVID-19 outbreak | 21-May-20 | 07:00 | RNS |
Lynparza approved in the US for prostate cancer | 20-May-20 | 07:00 | RNS |
Enhertu US Breakthrough status for lung cancer | 18-May-20 | 07:00 | RNS |
Date | Broker Name | Rec | Price | Old Price Target | New Price Target | Broker Change |
---|---|---|---|---|---|---|
12-Apr-21 | Shore Capital | Buy | 7225.00p | 0.00p | 0.00p | Reiteration |
08-Apr-21 | Deutsche | Buy | 7287.00p | 0.00p | 10200.00p | Reiteration |
08-Apr-21 | Citigroup | Buy | 7287.00p | 0.00p | 10000.00p | Reiteration |
14-Jan-21 | Berenberg Bank | Buy | 7662.00p | 105.00p | 100.00p | Reiteration |
14-Jan-21 | Barclays | Overweight | 7559.00p | 0.00p | 0.00p | Reiteration |
17-Dec-20 | Liberum Capital | Buy | 7542.00p | 9770.00p | 9430.00p | Reiteration |
23-Nov-20 | Morgan Stanley | Equal-weight | 8000.00p | 9000.00p | 9400.00p | Reiteration |
17-Nov-20 | Jefferies | Buy | 8180.00p | 0.00p | 8100.00p | Reiteration |
03-Nov-20 | JP Morgan Cazenove | Overweight | 7963.00p | 0.00p | 9500.00p | Reiteration |
08-Jun-20 | Credit Suisse | Outperform | 8244.00p | 9000.00p | 9000.00p | Reiteration |